Ionis Pharmaceuticals price target raised to $80 from $70 at RBC Capital

RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $70 and keeps an Outperform rating on the shares. The firm’s discussion with a key opinion leader over the recent Phase 3 data for olezarsen in severe hypertriglyceridemia saw the cardiologist offer an enthusiastic take as this is the very first agent to show a benefit in acute pancreatitis in a prospective randomized clinical trial, the analyst tells investors in a research note.